Expanding treatment options for resectable gastric cancer: Is it a countdown for radiotherapy?

HIZAL M., ŞENDUR M. A. N., BİLGİN B., AKINCI M. B., Dede D., YALÇIN B.

Journal of B.U.ON., vol.24, no.4, pp.1367-1370, 2019 (SCI-Expanded, Scopus) identifier identifier

  • Publication Type: Article / Review
  • Volume: 24 Issue: 4
  • Publication Date: 2019
  • Journal Name: Journal of B.U.ON.
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1367-1370
  • Ankara Yıldırım Beyazıt University Affiliated: Yes

Abstract

Chemoradiotherapy (CRT) and chemotherapy in the perioperative or postoperative settings are the different neoadjuvant/adjuvant treatment approaches for resectable gastric cancer. After the results of the ARTIST trial, CRT lost its importance on a large scale in the adjuvant setting. Also, according to the results of the CRITICS trial, CRT does not seem beneficial in the perioperative treatment setting. The beneficial effect of neoadjuvant/adjuvant radiotherapy as a therapeutic option became more questionable as the evidence grows, but still needs further studies to identify its effects on a subgroup of patients who have R1 or